This trial is testing how well cytarabine, idarubicin, and daunorubicin work with or without pembrolizumab to treat patients with newly-diagnosed acute myeloid leukemia.
2 Primary · 6 Secondary · Reporting Duration: From randomization to failure to achieve CR/CRi, relapse or death from any cause, assessed up to 5 years
124 Total Participants · 2 Treatment Groups
Primary Treatment: Hematopoietic Cell Transplantation · No Placebo Group · Phase 2
Age 18 - 75 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: